ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer

FRIDAY, June 9, 2023 -- For patients with locally advanced or metastatic renal cell carcinoma with disease progression on or after immune checkpoint inhibitor treatment, the addition of atezolizumab to cabozantinib does not improve clinical...